Jamalpoor Amer, Sparidans Rolf W, Pou Casellas Carla, Rood Johannes J M, Joshi Mansi, Masereeuw Rosalinde, Janssen Manoe J
Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Utrecht, The Netherlands.
Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
Biomed Chromatogr. 2018 Aug;32(8):e4238. doi: 10.1002/bmc.4238. Epub 2018 Apr 15.
Nephropathic cystinosis is characterized by abnormal intralysosomal accumulation of cystine throughout the body, causing irreversible damage to various organs, particularly the kidneys. Cysteamine, the currently available treatment, can reduce lysosomal cystine and postpone disease progression. However, cysteamine poses serious side effects and does not address all of the symptoms of cystinosis. To screen for new treatment options, a rapid and reliable high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed to quantify cystine in conditionally immortalized human proximal tubular epithelial cells (ciPTEC). The ciPTEC were treated with N-ethylmaleimide, lysed and deproteinized with 15% (w/v) sulfosalicylic acid. Subsequently, cystine was measured using deuterium-labeled cystine-D4, as the internal standard. The assay developed demonstrated linearity to at least 20 μmol/L with a good precision. Accuracies were between 97.3 and 102.9% for both cell extracts and whole cell samples. Cystine was sufficiently stable under all relevant analytical conditions. The assay was successfully applied to determine cystine levels in both healthy and cystinotic ciPTEC. Control cells showed clearly distinguishable cystine levels compared with cystinotic cells treated with or without cysteamine. The method developed provides a fast and reliable quantification of cystine, and is applicable to screen for potential drugs that could reverse cystinotic symptoms in human kidney cells.
肾病性胱氨酸病的特征是胱氨酸在全身溶酶体内异常蓄积,对各个器官,尤其是肾脏造成不可逆损害。目前可用的治疗药物半胱胺可以减少溶酶体中的胱氨酸并延缓疾病进展。然而,半胱胺有严重的副作用,且无法解决胱氨酸病的所有症状。为了筛选新的治疗方案,我们开发了一种快速可靠的高效液相色谱-串联质谱法(HPLC-MS/MS)来定量有条件永生化的人近端肾小管上皮细胞(ciPTEC)中的胱氨酸。用N-乙基马来酰亚胺处理ciPTEC,然后用15%(w/v)磺基水杨酸进行裂解和脱蛋白。随后,以氘代胱氨酸-D4作为内标物来测定胱氨酸。所开发的检测方法在至少20μmol/L范围内呈线性,精密度良好。细胞提取物和全细胞样品的准确度均在97.3%至102.9%之间。胱氨酸在所有相关分析条件下都足够稳定。该检测方法已成功应用于测定健康和患有胱氨酸病的ciPTEC中的胱氨酸水平。与用或未用半胱胺处理的患有胱氨酸病的细胞相比,对照细胞的胱氨酸水平有明显差异。所开发的方法能够快速可靠地定量胱氨酸,适用于筛选可能逆转人肾细胞中胱氨酸病症状的潜在药物。